Request Demo

Last update 18 Sep 2025

Mupirocin

Last update 18 Sep 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryMupirocin, also known by its brand name CENTANY®, is a small molecule drug that works as an RNA synthetase inhibitor to treat bacterial infections. It is commonly used to treat impetigo and other skin infections caused by Gram-positive bacteria. Originally developed by GSK, Mupirocin was first approved for use in 1987. CENTANY® ointment is a topical medication used to treat impetigo by inhibiting bacterial growth and stopping the spread of infection.

Drug Type

Small molecule drug

Synonyms

Bactroban Nasal, Mupirocin (USP/INN), Mupirocin cream

+ [6]

Target

Bacterial IRS

Action

inhibitors

Mechanism

Bacterial IRS inhibitors(Bacterial isoleucyl-tRNA synthetase inhibitors)

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal Diseases

Active Indication

ImpetigoSecondary infectionGram-Positive Bacterial Infections+ [1]

Inactive Indication-

Originator Organization

GSK Plc

Active Organization

GlaxoSmithKline Australia Pty Ltd.

Revium Rx

Nanjing Indetek Pharmaceutical Technology Co., Ltd.

+ [3]

Inactive Organization

GSK Plc

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (31 Dec 1987),

Impetigo

Regulation-

Structure/Sequence

Molecular FormulaC26H44O9

InChIKeyMINDHVHHQZYEEK-HBBNESRFSA-N

CAS Registry12650-69-0

Clinical Trials associated with Mupirocin

NCT06712433

/ Not yet recruitingPhase 2IIT

Bacterial Decolonization Plus Intraoperative Indocyanine Green Angiography for Soft Tissue Sarcomas of the Lower Extremity Receiving Preoperative Radiotherapy (CONCERTO)

This trial will investigate the combination of two low-cost, non-toxic strategies to assess whether they can reduce the risk of acute major wound complications in soft tissue sarcoma of the lower extremity. Intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to radiation therapy and repeated for 5 days every 2 weeks during radiation therapy may significantly reduce the risk of acute radiation dermatitis. That, along with use of indocyanine green (ICG) angiography at the time of wound closure.

Start Date31 Oct 2025

Sponsor / Collaborator

University of Pittsburgh

NCT06541145

/ RecruitingNot ApplicableIIT

Impact of Bacterial Decolonization on Bacterial Burden Within Maternal-infant Dyads

The goal of this study is to measure bacterial burden, specifically Staph aureus, and how it spreads between mothers and their infants. Researchers will evaluate if the amount of bacteria on their skin remains the same after mothers use a skin antisepsis treatment prior to delivering their infants. The investigators also aim to assess participant interest in and compliance with skin antisepsis treatments. The hypothesis is that increased maternal interest will align with increased treatment compliance.

Start Date21 Aug 2024

Sponsor / Collaborator

Duke University

[+1]

NCT06210594

/ RecruitingPhase 4IIT

SHIELD (Staph Intervention for Effective Local Defense): An Open-label Randomized Controlled Trial to Assess Efficacy of a Sustained Intervention (Topical Antibiotics and Skin Antisepsis) to Decrease Staphylococcus Aureus Carriage in Adults

Indigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections. The goal of this clinical trial is to evaluate a community-informed approach to reduce carriage of SA. Participants will be assigned to education and household supplies for prevention of SA with and without a biomedical intervention. Researchers will compare SA carriage in the two groups.

Start Date01 Apr 2024

Sponsor / Collaborator

Johns Hopkins Bloomberg School of Public Health

[+1]

100 Clinical Results associated with Mupirocin

100 Translational Medicine associated with Mupirocin

100 Patents (Medical) associated with Mupirocin

2,727

Literatures (Medical) associated with Mupirocin

01 Dec 2025·Biomaterials advances

Porous hydrogel of siloxane-modified polyvinyl alcohol/polydopamine containing berberine chloride, exhibiting robust antibacterial activity and promoting the healing of MRSA-infected wounds

Article

Author: Hamishehkar, Hamed ; Farahpour, Mohammad Reza ; Kiumarsi, Amirhossein ; Tabatabaei, Zohreh Ghazi

Advanced and novel effective wound dressings that decrease wound infections are essential for clinical application. In this study, a multifunctional hydrogel was engineered based on polyvinyl alcohol (PVA), polydopamine (PDA), and porous silica (PSi), loaded with berberine chloride (Bbn), for the treatment of MRSA-infected wounds. The PVA@PSi/PDA-Bbn hydrogel was fabricated via sol-gel and self-polymerization methods, forming a porous, adhesive, and photothermal-responsive matrix. The hydrogel demonstrated excellent swelling behavior, mechanical strength, and sustained Bbn release under NIR irradiation. The efficacy of the hydrogels was evaluated through antibacterial activity, pathological assessments, and the expression of key proteins involved in cell proliferation and wound healing. These proteins included cyclin D1, c-Myc, Max, FGF-1, β-catenin, and WNT-1, and COL1A. The physicochemical properties of the hydrogels confirmed their successful synthesis and suitability for biomedical applications. The results for swelling, rheological properties, adhesive strength, safety, and antibacterial activity confirmed the hydrogels to be appropriate. The PVA@PSi40/PAD-Bbn hydrogel could enhance the healing process through its antibacterial activity and modulation of the expressions of cyclin D1, c-Myc, Max, FGF-1, β-catenin, and COL1-A. In sum, PVA@PSi40/PAD-Bbn could compete with the mupirocin ointment® and accelerate the MRSA-wound healing process. It showed better performance than conventional treatments by providing controlled drug release, strong tissue adhesion, and effective MRSA inhibition to promote wound healing.

01 Nov 2025·Current drug discovery technologies

Virtual Screening and Identification of Novel Oxindole Derivatives as Potential Antimicrobial Agents

Article

Author: Gnanavelou, Revathi ; Perinbaraj, Sowmiya ; Girija, Konda Reddy

Introduction::

Antimicrobial resistance (AMR), according to the World Health Organi-zation, is one of the most serious risks to global public health and development. It is a serious health hazard, with over 10 million deaths expected by 2050. New treatment materials and ways to remove AMR pathogens are in great demand to combat illnesses caused by such bacteria. Hence, the current work focused on virtual screening of the therapeutic potential of new oxindole derivatives against the targeted enzymes for antibacterial activity.

Materials and Methods::

A series of 120 novel 3-substituted-2-oxindole derivatives were designed based on the literature and SAR study, which were screened for their binding affinity against tar-geted enzymes, such as methionyl-tRNA synthetase (1PFV) and tyrosyl-tRNA synthetase (1JIL) using AutoDock Vina software. Compounds with significant binding energy were identified and filtered for appropriate ADME properties using the SwissADME program. Furthermore, the top fifteen hit compounds were evaluated for toxicity risk and drug score with the pkCSM online tool and OSIRIS Property Explorer, respectively.

Results and Discussion::

The docking analysis of the top two hits revealed that compounds 4 and 6 had a binding affinity of -10.1 Kcal/mol and -10.0 Kcal/mol against the targeted enzymes, respec-tively, compared to the standard (Tetracycline -9.3 Kcal/mol and Mupirocin -7.5 Kcal/mol).

Conclusion::

Hence, the best-hit compound 4 underwent MD simulation, validating its stability and successfully satisfying all in silico parameters, necessitating further synthesis and screening for in-vitro antimicrobial activity. These novel oxindole scaffolds could thus serve as promising leads for effective antibacterial drugs.

01 Oct 2025·BIOCHIMIE

5-(3, 4-methylenedioxyphenyl)-4-ethyl-2E, 4E-pentadienoic acid piperidide as MdeA efflux pump inhibitor of Staphylococcus aureus

Article

Author: Khan, Inshad Ali ; Saran, Saurabh ; Kalia, Nitin Pal ; Singh, Samsher ; Chauhan, Narendra Singh ; Bhat, Rahul ; Yadav, Govind ; Koul, Surrinder ; Jeena, Neha

The analogue of piperine 5-(3,4-methylenedioxyphenyl)-4-ethyl-2E,4E-pentadienoic acid piperidide (IIIM-1133), was evaluated in this in combination with pseudomonic acid A, commonly known as mupirocin against of S. aureus including Methicillin Resistant S. aureus (MRSA). Initial screening of compound revealed an increase in the potency of mupirocin, with a reduction in the minimum inhibitory concentration (MIC) values from 0.25 μg/mL to 0.06 μg/mL in case of wild type and MRSA strains of S. aureus and from 256 μg/mL to 32 μg/mL in mup^r-1 strain. The combination decreased the mutation frequency against mupirocin in wild-type S. aureus. The demonstrated ability of IIIM-1133 to suppress ethidium bromide efflux in MdeA-overexpressing S. aureus Mup^r-1 substantiated its effectiveness as an efflux pump inhibitor. Docking studies demonstrated that IIIM-1133 binds strongly in the substrate pocket of the MdeA efflux pump, highlighting its potential as an efflux pump inhibitor. IIIM-1133 alone and in combination with mupirocin was found to be nontoxic when tested on RAW 264.7 cells lines. A topical formulation of 2 % mupirocin with 0.5 % IIIM-1133 showed better efficacy in reducing the bacterial load in the infected site and sterilizing the infected patch. Furthermore, the formulation revealed better tissue healing potential with an anti-inflammatory activity by suppressing Il-6 and TNF-α. This formulation exhibited better efficacy than markedly available 2 % mupirocin.

News (Medical) associated with Mupirocin

13 May 2025

·www.prnewswire.com

iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization

Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections Demonstrated its Efficacy and Safety through previous Clinical Trials Company seeks global partners to co-develop toward Commercialization SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and unmet medical needs, today announced the strategic initiative aimed at expanding the clinical applications of SAL200 and seeking a strategic partnership to target the prevention of surgical site infections (SSIs) by nasal MRSA decolonization. Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most dangerous superbugs worldwide, with rising infection rates in both hospital and community settings. Even in sterile operating environments, MRSA-related SSIs frequently originate from the patient's own nasal or skin, potentially leading to extended hospital stays, increased treatment costs, and in severe cases, serious systemic infections such as sepsis, osteomyelitis, or endocarditis. High-risk surgical patients including those undergoing implant or cardiac surgeries, or those with compromised immune systems face significantly elevated risks of MRSA infections. Although mupirocin-based nasal ointments have been used as a standard of care product for the prevention of SSI, resistance rates are continuously increasing, leaving clinicians with few effective solution. As an intravenous injection drug for infective endocarditis and bacteremia, SAL200 has already demonstrated a strong safety profile through Phase 1a/1b and Phase 2a clinical trials. Encouraged by recent feedback from key clinical experts, iNtRON is now pursuing an additional indication for SAL200 as a pre-operative MRSA nasal decolonization solution. According to recent industry reports, the global nasal decolonization market which is closely related to SSI prevention was valued at USD 1.6 billion in 2024 and is projected to grow at a CAGR of 7.5%, driven by heightened hospital infection control regulations and growing concern over antimicrobial resistance. With the strategic expansion of the clinical application of SAL200 for the promising market opportunity, iNtRON is seeking global partners to co-develop a new formulation, delivery route, and product type as a nasal or topical use, and to collaborate on preclinical and clinical studies aimed at commercialization. "As SAL200 has demonstrated its strong efficacy and safety as an I.V. injection formulation in the previous clinical studies, we believe it can be developed into a nasal or topical use formulation through a much simplified clinical trial process" said YOON Kyung Won, CEO. "We believe SAL200 can fill a critical gap in MRSA nasal decolonization, an area in urgent need of a new solution. We aim to begin clinical development for this new indication in 2025 and are confident that our novel solution will significantly advance efforts to prevent MRSA-related SSIs. We are open to all types of partnerships including co-development and licensing, and welcome discussion with those who share our vision." About iNtRON Biotechnology, Inc. iNtRON Biotechnology () is a clinical-stage biopharmaceutical company at the forefront of bacteriophage-derived technology and immune therapeutics. The company specializes in developing first-in-class and first-in-concept bio-drugs to combat infectious diseases and immune-related disorders. Since its foundation and subsequent IPO on KOSDAQ, iNtRON has focused on global R&BD collaborations and is committed to delivering innovative therapies that address urgent medical needs in infectious disease and immunotherapy. Contact Us YOON, Kyung Won (Kevin) / CEO, Vice President / [email protected] SHIN, Tae Kyu (TK) / BD Team Leader / [email protected] it is iNtRON. SOURCE iNtRON Biotechnology, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

26 Sep 2024

·www.haleon.com

Haleon to increase stake in China JV to 88%

Haleon plc (“Haleon”) (LSE/NYSE: HLN) today announces that it has entered into an agreement to acquire an additional 33% equity interest in Tianjin TSKF Pharmaceutical Co. Ltd (“TSKF”), its joint venture in China from its partners, Tianjin Pharmaceutical Group (“TPG”) and Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (“DRTG”) for a total consideration of RMB 4,465 million (c. £0.5 billion). TSKF accounted for c. 40% of Haleon’s China revenues in FY 2023 and manufactures and/or distributes leading brands such as Fenbid, Voltaren and Bactroban. This acquisition will increase Haleon’s participation in TSKF from 55% to 88% and deliver greater control and increased strategic and operational flexibility across the business. The acquisition is expected to be funded through a combination of Haleon’s existing cash resources and new third-party Renminbi-denominated debt. Subject to customary closing conditions, including the approval of DRTG’s shareholders and applicable regulatory clearances, the transaction is expected to close end of 2024 and to be accretive to EPS. In addition, Haleon and DRTG have agreed, effective from closing of the acquisition, that Haleon would have an option to acquire and DRTG an option to sell the remaining 12% shareholding in TSKF. Brian McNamara, Chief Executive Officer of Haleon commented: "China is a key strategic market for Haleon. Over the last three years, it has delivered strong market share growth and our acquisition of a further 33% in our JV partnership is an important milestone which is both strategically and commercially compelling. It reflects our commitment to this important market, the exceptional growth potential we see in China and is fully consistent with our capital allocation priorities to drive attractive returns for shareholders and maintain a strong investment grade balance sheet.

Acquisition

13 Dec 2023

·www.businesswire.com

Ondine Successfully Raised C$4.91 Million to Support Acceleration of Its Commercial Rollout of Nasal Decolonization to Prevent Healthcare-associated Infections

VANCOUVER, Canada--( BUSINESS WIRE )--Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens – bacteria, viruses and fungi – without causing antimicrobial resistance. The company has confirmed that it has more than doubled the number of Steriwave ® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global focus on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine’s photodisinfection technology. The deployments are in areas of major surgery, including spinal, orthopedic, and cardiovascular. The antibiotic mupirocin has been used for nasal decolonization for the prevention of HAIs since the 1980s. However, mupirocin has resistance rates of up to 81%, 2 and very poor compliance. 3 Carolyn Cross, CEO of Ondine, commented, "We have put great efforts into improving our commercial activity sales process, which has increased the speed of the average sales cycle from contact to deployment by 50%. We have appointed distributors in the UK, Spain, and Mexico and are gaining real momentum. What is particularly encouraging is that many hospitals are recommending Steriwave to other hospitals. We believe this momentum will continue to increase, and commercial sales will become more significant in 2024.” The five-minute Steriwave nasal decolonization procedure is easy to incorporate into the pre surgery procedures. It is painless and very well received by patients who are often intrigued by the process. There have been no reports of serious side effects as a result of Steriwave usage. Steriwave has been used by more than 150,000 patients, including at Vancouver General Hospital where its use has been associated with a significant reduction in HAIs across major surgeries. 4,5 As well as growing its commercial activities, the company continues to work closely with HCA – the largest hospital group in the United States – to prepare for the Phase 3 trial in circa 14 HCA hospitals as part of its Ondine’s submission to the FDA for approval. The company already has approval for Steriwave in Canada, the UK, the EU, and Mexico. Implementing nasal decolonization prior to major surgery to reduce HAIs is recommended by leading medical bodies, including the World Health Organization, 6 the Society for Healthcare Epidemiology of America (SHEA), 7 and NICE. 8 The nose is the major reservoir of pathogens and the majority of surgical site infections (SSIs) and bloodstream infections have been traced back to bacteria in the patient’s nose. 9 A patient with a surgical site infection (SSI) will, on average, spend 7 to 11 days longer in the hospital, significantly increasing costs and lengthening patients' recovery. 10 While currently focusing on nasal decolonization, Ondine’s patented photodisinfection technology will be developed to prevent and treat a wide variety of topical infections. About Ondine Biomedical Inc. Ondine Biomedical Inc. is a Canadian life science company pioneering the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications. 1 Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):417-22. doi: 10.1586/erp.09.53. PMID: 19817525; PMCID: PMC2827870. 2 Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother . 2015;70(10):2681-2692. doi:10.1093/jac/dkv169 3 Hansen D, Patzke PI, Werfel U, Benner D, Brauksiepe A, Popp W. Success of MRSA eradication in hospital routine: depends on compliance. Infection. 2007 Jun;35(4):260-4. doi: 10.1007/s15010-007-6273-y. Epub 2007 Jul 23. PMID: 17646910. 4 Bryce E, Wong T, Forrester L, Masri B, Jeske D, Barr K, Errico S, Roscoe D. Nasal photodisinfection and chlorhexidine wipes decrease surgical site infections: a historical control study and propensity analysis. J Hosp Infect. 2014 Oct;88(2):89-95. doi: 10.1016/j.jhin.2014.06.017. Epub 2014 Aug 1. Erratum in: J Hosp Infect. 2015 Sep;91(1):93. PMID: 25171975. 5 Moskven E, Banaszek D, Sayre E, Gara A, Bryce E, Wong T, Ailon T, Charest-Morin R, Dea N., Dvorak M, Fisher C, Kwon B, Paquette S, Street J. Effectiveness of prophylactic intranasal photodynamic disinfection therapy and chlorhexidine gluconate body wipes for surgical site infection prophylaxis in adult spine surgery. Can J Surg. 2023 Nov;66(6), E550–E560. https://doi.org/10.1503/cjs.016922 6 World Health Organization. Global Guidelines for the Prevention of Surgical Site Infection. World Health Organization; 2016. Available at: https://www.who.int/publications/i/item/9789241550475 . Accessed December 12, 2023. 7 Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67 8 National Institute for Health and Care Excellence (NICE). NICE Surgical Site Infections: Prevention and Treatment. NICE; 2019. Available at: https://www.nice.org.uk/guidance/ng125 . Accessed December 12, 2023. 9 von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001 Jan 4;344(1):11-6. doi: 10.1056/NEJM200101043440102. PMID: 11136954. 10 Seidelman JL, Mantyh CR, Anderson DJ. Surgical Site Infection Prevention: A Review. JAMA. 2023;329(3):244–252. doi:10.1001/jama.2022.24075

Phase 3Drug Approval

100 Deals associated with Mupirocin

External Link

KEGG	Wiki	ATC	Drug Bank
D01076	Mupirocin	R01AX06 D06AX09	DB00410

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Secondary infection	Australia	GlaxoSmithKline Australia Pty Ltd.	03 Apr 1998
Gram-Positive Bacterial Infections	China	Sino-American Tianjin SmithKline & French Lab Ltd.	01 Jan 1993
Impetigo	United States	GSK Plc	31 Dec 1987

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacterial Infections	Preclinical	Israel	Revium Rx	01 Sep 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02127658 (MEDiC, CTgov)	Phase 4	-	14	Hygiene education (Hygiene Education)	ytcoesdnxv = dxrnmrnpku gkwtkwnaei (ovoxohtiaf, zjjnwiepzp - vbnblzbyes) View more	-	25 Jun 2024
				Sodium Hypochlorite+Mupirocin ointment (Hygiene Education and Decolonization)	ytcoesdnxv = bwzpksawvu gkwtkwnaei (ovoxohtiaf, hiaboumfjl - lgpqdonguk) View more
NCT03140423 (CTgov)	Phase 4	Sepsis	353,323	Mupirocin (Arm 1: Routine Care (Mupirocin/CHG))	svqxlnillw = psewrrtjdr cqzxaaoive (xgwfptdmux, zphcsujkrb - wmljvprtsh) View more	-	07 Feb 2024
				Arm 2. Iodophor/CHG Decolonization (Arm 2: Iodophor/CHG Decolonization)	svqxlnillw = htoijaniov cqzxaaoive (xgwfptdmux, smvwotshch - imkglxqghz) View more
NCT03883828 (ASCO2022) Manual	Phase 2/3	Radiodermatitis	76	mupirocin+Chlorhexidine gluconate	kmlrexwndc(xbznscnksv) = dfieakbnpw bcpukozayu (wzqnubvrkn ) View more	Positive	08 Jun 2022
				standard of care	kmlrexwndc(xbznscnksv) = lbpwbnljga bcpukozayu (wzqnubvrkn ) View more
NCT03673956 (CTgov)	Phase 1/2	Chronic sinusitis	19	Tobramycin (Tobramycin Topical Antibiotic Nasal Saline Rinse)	gkkgrlqrry = oxjrfrwgoh agykumubtf (sofvkhafsf, wqlgaspamd - kyxilikimn) View more	-	20 Apr 2022
				levofloxacin (Levofloxacin Topical Antibiotic Nasal Saline Rinse)	gkkgrlqrry = tnsibziqdr agykumubtf (sofvkhafsf, oiuuwrpzdq - ewtlcqnpdj) View more
NCT02967432 (Pubmed \| J Pediatr)	Phase 2	-	216	Topical Mupirocin	xrctvspyqn(ttwjhxycyg) = piuwsnvghq bvmeeiintk (iyhoxizjrf ) View more	-	20 May 2021
				Placebo	xrctvspyqn(ttwjhxycyg) = eegevwqwjv bvmeeiintk (iyhoxizjrf ) View more
NCT04218799 (CTgov)	Phase 4	Cross Infection	19	Chlorhexidine+Mupirocin	wbcojvsxzj(wrqvqtehfw) = nrnojugagb iqxkdxbjzj (vznlwcfhan, 11003) View more	-	24 Apr 2020
NCT02223520 (TREAT PARENTS, CTgov)	Not Applicable	Staphylococcus Aureus Infections \| Staphylococcus aureus bacteraemia \| Staphylococcal Infections	307	Chlorhexidine+Mupirocin (Mupirocin and Chlorhexidine)	mfhkojpxvc = fafkbutgut cksbtqhbfg (vjiyeuvupi, pujtysvdcs - htusvnvhcf) View more	-	16 Mar 2020
				Placebo ointment and placebo cloths (Placebo Ointment and Placebo Cloths)	mfhkojpxvc = asyqpooxbw cksbtqhbfg (vjiyeuvupi, wadhumydjy - qeqlcfijir) View more
NCT02218307 (CTgov)	Phase 4	Chronic sinusitis	68	Mupirocin (Mupirocin)	vhhqyqzjcn(sdenbujptj) = skcmhjxhvy ekgloqcawv (hiizvfclld, 19.23) View more	-	09 Mar 2017
				Placebo (Placebo)	vhhqyqzjcn(sdenbujptj) = pweppgxudp ekgloqcawv (hiizvfclld, 17.33) View more
NCT02284555 (CTgov)	Phase 4	Staphylococcal Infections	12	Mupirocin	fzsfjvlcvq = sychpzzvwa ksyqievoev (zugtafphox, dmluxwgyhx - pnkvfdyihu) View more	-	01 Mar 2016
NCT00108160 (CTgov)	Phase 4	Staphylococcal Infections	146	Mupirocin Ointment [Treatment] (Mupirocin Ointment [Treatment])	iteqwbfgnt = tqyooxtitx ojbumynjfa (hnlcqhcntz, dnkubeendu - kubbogcoby) View more	-	04 Feb 2014
				Polyethylene Glycol Ointment [Placebo] (Polyethylene Glycol Ointment [Placebo])	iteqwbfgnt = pvwgtwwbqd ojbumynjfa (hnlcqhcntz, wgibjytbem - rmfmzjcbsh) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis